REGENXBIO, Inc. (RGNX)
9.50
-0.16
(-1.66%)
USD |
NASDAQ |
Aug 31, 16:00
9.51
+0.01
(+0.11%)
After-Hours: 20:00
REGENXBIO Total Long Term Debt (Quarterly) : 243.11M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 243.11M |
| March 31, 2026 | 240.53M |
| December 31, 2025 | 252.23M |
| September 30, 2025 | 259.07M |
| June 30, 2025 | 263.64M |
| March 31, 2025 | 125.58M |
| December 31, 2024 | 133.82M |
| September 30, 2024 | 138.09M |
| June 30, 2024 | 151.41M |
| March 31, 2024 | 163.50M |
| December 31, 2023 | 82.22M |
| September 30, 2023 | 84.06M |
| June 30, 2023 | 85.25M |
| March 31, 2023 | 86.99M |
| December 31, 2022 | 88.80M |
| September 30, 2022 | 84.67M |
| June 30, 2022 | 85.67M |
| March 31, 2022 | 85.57M |
| December 31, 2021 | 84.93M |
| September 30, 2021 | 83.88M |
| June 30, 2021 | 82.38M |
| March 31, 2021 | 75.08M |
| December 31, 2020 | 70.15M |
| September 30, 2020 | 57.46M |
| Date | Value |
|---|---|
| June 30, 2020 | 7.085M |
| March 31, 2020 | 7.99M |
| December 31, 2019 | 8.874M |
| September 30, 2019 | 4.32M |
| June 30, 2019 | 4.654M |
| March 31, 2019 | 5.483M |
| December 31, 2018 | 5.854M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AbbVie, Inc. | 70.82B |
| Capricor Therapeutics, Inc. | 89.56M |
| Biogen, Inc. | 8.355B |
| United Therapeutics Corp. | 0.00 |
| Ardelyx, Inc. | 254.64M |